July FDA approvals delivered first products for three biotechs, including Vera Therapeutics’ accelerated approval for Trutakna (atacicept) in primary immunoglobulin A nephropathy, with Celcuity preparing Revtorpyk (gedatolisib) and Outlook Therapeutics moving forward with Lytenava (bevacizumab) for wet AMD. The approvals also underline how near-term product launch strategies are aligning around differentiated mechanisms and formulation advantages, from systemic immunology to eye-specific delivery. For the sector, the set of first-off-the-block approvals offers a snapshot of where late-stage risk is being rewarded—and where commercial execution will quickly determine whether investors see durable value creation.